Contributors: Institut de biologie de l'ENS Paris (IBENS); Département de Biologie - ENS Paris; École normale supérieure - Paris (ENS-PSL); Université Paris Sciences et Lettres (PSL)-Université Paris Sciences et Lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Paris (ENS-PSL); Université Paris Sciences et Lettres (PSL)-Université Paris Sciences et Lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS); Institut Pasteur Paris (IP); Université Paris Cité (UPCité); Institut Pasteur Korea - Institut Pasteur de Corée; Réseau International des Instituts Pasteur (RIIP); This study received fundings from (i) the French Government “Investissement d’Avenir” program, Labex IBEID, with the reference ANR-10-LABX-62-IBEID, (ii) the French Alliance pour les Sciences de la Vie et de la Santé (AVIESAN), ITMO I3M, (iii) the PSL University, through the PSL pré-maturation program, AMPlify project, with the reference C22-78/2022-425, and (iv) the European Union, through the European Innovation Council Pathfinder Open program, MaxImmun project, with the reference 101129622.; ANR-10-LABX-0062,IBEID,Integrative Biology of Emerging Infectious Diseases(2010); European Project: 101129622,HORIZON-EIC-2023-PATHFINDEROPEN-01 ,MaxImmun(2024)
نبذة مختصرة : International audience ; The human intestinal tract is colonized with microorganisms, which present a diverse array of immunological challenges. A number of antimicrobial mechanisms have evolved to cope with these challenges. A key defense mechanism is the expression of inducible antimicrobial peptides (AMPs), such as beta-defensins, which rapidly inactivate microorganisms. We currently have a limited knowledge of mechanisms regulating the inducible expression of AMP genes, especially factors from the host required in these regulatory mechanisms. To identify the host factors required for expression of the beta-defensin-2 gene ( HBD2 ) in intestinal epithelial cells upon a bacterial challenge, we performed a RNAi screen using a siRNA library spanning the whole human genome. The screening was performed in duplicate to select the strongest 79 and 110 hit genes whose silencing promoted or inhibited HBD2 expression, respectively. A set of 57 hits selected among the two groups of genes was subjected to a counter-screening and a subset was subsequently validated for its impact onto HBD2 expression. Among the 57 confirmed hits, we brought out the TLR5-MYD88 signaling pathway, but above all new signaling proteins, epigenetic regulators and transcription factors so far unrevealed in the HBD2 regulatory circuits, like the GATA6 transcription factor involved in inflammatory bowel diseases. This study represents a significant step toward unveiling the key molecular requirements to promote AMP expression in human intestinal epithelial cells, and revealing new potential targets for the development of an innovative therapeutic strategy aiming at stimulating the host AMP expression, at the era of antimicrobial resistance.
No Comments.